Improving access to novel heart failure agents through a defined multidisciplinary pathway

ConclusionsDespite considerable therapeutic advances and emerging device therapies, heart failure remains a tremendous medical and socioeconomic problem. There is a compelling need for improved clinical treatment for this complex population, and novel heart failure medication therapies has shown tremendous promise in improving health outcomes and quality of life in these patients. By defining a multidisciplinary pathway that has allowed access to these new, promising heart failure agents, our institution has allowed access to medication therapies that typically were not being filled and/or prescribed at other clinics and hospitals secondary to high costs or increased workload on staff secondary to prior tedious authorizations. We believe this multidisciplinary pathway approach can generalized and used in any area of medicine to help with obtaining novel therapies.(*I am in the process of getting the data from our pharmacy and EMR team here regarding the fill rate and nonfill rate at our institution of sacubitril/valsartan and corlanor since FDA approved but unfortunately will not have these numbers until early November. If approved, I will include in this poster presentation)ResultsOur defined multidisciplinary pathway:
Source: Heart and Lung: The Journal of Acute and Critical Care - Category: Respiratory Medicine Source Type: research